Merck discontinues antibiotic Recarbio in the U.S. despite superbug concerns

Merck has discontinued the antibiotic Recarbio in the U.S. market earlier this month. Approved seven years ago as a last-resort treatment by the Food and Drug Administration to mitigate antibiotic resistance, the drug treats severe infections such as hospital- or ventilator-acquired pneumonia and complicated urinary and stomach infections.